Hepatic lesions induced by drugs include extremely diverse various clinical, biological and histological manifestations that can determine acute or chronic hepatobiliary disease. The term of hepatitis is recommended to be used when there is a histological confirmation. In the last decades a 11 time increase of the hepatic lesions induced by drugs is reported, due both to the increase of the number of used drugs but also by their more frequent recognition. We carried out a combined retrospective study and longitudinally prospective study that included patients with drug hepatitis. In our study there were 83 cases of drug hepatitis at AINS, which represents 33.46 % of the total number of 248 patients with drug hepatitis. In our study the highest drug hepatitis at AINS were Nimesulid (24 cases), followed by Diclofenac (21 cases), and the fewest at Piroxicam (9 cases). All the cases from the study were symptomatic, showing the increase of the cytolysis enzymes and sometimes cholestasis enzymes (mainly GGT).
Introduction
Hepatic lesions induced by drugs include extremely diverse various clinical, biological and histological manifestations that can determine acute or chronic hepatobiliary disease. The term of hepatitis is recommended to be used when there is a histological confirmation. In the last decades a 11 time increase of the hepatic lesions induced by drugs is reported, due both to the increase of the number of used drugs but also by their more frequent recognition. The clinical criteria are of practical utility because they draw attention on the drug etiology.
The clinical diagnosis is based on:
• disease occurrence chronology-includes the relation between the drug intake and the therapeutic accident occurrence; • regression of the symptomatology on the interruption of the treatment • reoccurrence after administration -the most certain criterion by which an isolated drug can be proven as cause of an adverse hepatic reaction • the fostering fi eld -hepatic lesions induced by drugs are more frequent in women and they usually occur after the age of 40 years;
Material and method
We carried out a combined retrospective study and longitudinally prospective study that included patients with drug hepatitis. In our study there were 83 cases of drug hepatitis at AINS, which represents 33.46 % of the total number of 248 patients with drug hepatitis.
Inclusion criteria:
• ALAT increase (alanine aminotransferase) > 2N and/or FAS increase > 2N • AgHbs and Ac anti VHC negative • Anamnestic denial of alcohol consumption
Resul ts:
The distribution of the patients per decades of age and sex of the drug hepatitis cases are as follow: It can be noticed that the decade 60-69 was the most aff ected for the female gender and for the male gender the decade 50-59. There are some statistics that show that at the persons over 50 years the incidence of drug hepatitis increases.
The distribution of the patients with drug hepatitis according to the value of hepatic tests: for the 248 patients with drug hepatitis, the average value of the hepatic cytolysis tests were for TGO 92.45 ui and for TGP 95.74 ui. The colestatis tests had the following average values: total bilirubin of 1.35 mg/di, FAS of 68.04 ui and GGT of 44.48 UI (Figure 4 ).
In our study drug hepatits by hepatic cytolysis was dominant, more frequent than the cholestatic ones.
Figure 4 Descriptive statistics for biological markers
With regard to AINS hepatotoxicity, FDA concluded that it is a class characteristic of AINS.
There are genetic risk factors for drug hepatitis which are involved in 20-95% [I] and non genetic risk factors represented by age (adults are more predisposed than children), gender (women are more predisposed than men), race, obesity, malnutrition, sugar diabetes, steatosis, alcoholism, pre-existing hepatic diseases, drug (its hepatotoxic potential, doses), associated drugs and certain diseases (PR, LES) [2] .
Increases of transaminases are frequently associated with AINS utilization, yet hepatic failure is pretty rare [3] [4] . The net hepatic risk was illustrated in a retrospective study on 625000 patients who received more than 2 million prescriptions for AINS and who were evaluated for drug hepatitis at AINS [4] .
Diclofenac was reported to cause clinically manifest hepatitis, including ANA positivity and active chronic hepatitis histological evidence [5] .
The most frequent adverse hepatic reactions were reported at Sulindac, Diclofenac [6] [7] and at Nimesulid [8] . Ibuprofen is one of AINS that are least involved in the occurrence of hepatic lesions, but occasional cases of cytolythic or mixed cytolytic and cholestatic hepatic lesions were reported [9] [10] .
Piroxicam has a low incidence of drug hepatitis (1-2%) but cases of severe hepatitis were described fatal hepatic necrosis or that required transplant [11, 12] .
Conclusions:
The average age on diagnosis was 60,1 for the 248 patients, being lower for the male gender (57.47 years), against the female gender (61.26 years). Women were more affected, 69.35% being women and 30.64% men. In our study drug hepatitis by hepatic cytolysis was dominant, more frequent than the cholestatic ones.
In our study the highest number of drug hepatitis at AINS were Nimesulid (24 cases), followed by Diclofenac (21 cases), and the fewest at Piroxicam (9 cases). All the cases from the study were symptomatic, showing the increase of the cytolysis enzymes and sometimes cholestasis enzymes (mainly GGT).
Ketoprofen has a low incidence of adverse hepatic effects.
